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mproving Risk
tratification for Heart Failure
Role for Serial Testing of
-Type Natriuretic Peptides?*
atthew G. Daly, MB CHB,
hristopher M. Frampton, PHD,
ichard W. Troughton, MB CHB, PHD
hristchurch, New Zealand
he growing burden of heart failure (HF) in the elderly
opulation cannot be overstated (1–4). More than 9% of
merican men and close to 5% of women ages 60 to 79
ears report a diagnosis of HF, whereas above the age of 80
ears these figures increase to 13.8% and 12.2%, respectively
5). Increasing HF prevalence in the elderly population
eflects a steady or increasing incidence and greater survival
6–8). Despite reports of decreasing rates of first HF
ospitalization (9), the health care burden associated with
F is alarming: hospitalizations for HF in the U.S. ex-
eeded 1.1 million in 2006 (up from 877,000 in 1996), and
here were an estimated 3.4 million HF visits in the same
ear (5). As a result, the estimated direct and indirect health
are costs for HF in the U.S. alone exceed $37 billion in
009 (5). Projections into the middle part of this century
uggest that as the population ages, the prevalence and cost
f HF care will continue to increase (2).
See page 441
Early identification of subjects in HF stage A who are at
isk of developing overt HF is therefore a key HF preven-
ion strategy that is emphasized in current guidelines (1,2).
his strategy rightly targets the optimal treatment of pre-
isposing risk factors for HF, including hypertension, cor-
nary artery disease, and diabetes (10–12). Although two-
hirds of the population-attributable risk for new HF events
an be related to conventional risk factors, a substantial
ortion of incident HF within the community is not readily
xplained by considering these factors alone (4,10,13,14). In
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiology Department, Christchurch Hospital and the University ofo
tago, Christchurch, New Zealand. Dr. Troughton has received honoraria (modest)
rom Roche Diagnostics.he elderly population, in which HF poses specific chal-
enges—including higher rates of preserved left ventricular
jection fraction and greater comorbidity attributable to
enal dysfunction, anemia, and atrial fibrillation—prediction
f incident HF based on conventional risk factors may be
ess reliable (15).
Consequently, there is great interest in whether biomar-
er testing can identify subjects at risk for new HF or
ardiovascular events (13,14,16). Among the plethora of
iomarkers contributing to HF pathophysiology, the B-type
atriuretic peptides (B-type natriuretic peptide [BNP] and
-terminal pro–B-type natriuretic peptide [NT-proBNP])
ave received much attention (17). It is intuitively appealing
hat these peptides secreted primarily from cardiac myocytes
n response to volume or pressure overload should be
ccurate early markers of HF (17). This has proven true for
cutely symptomatic patients, in whom plasma BNP/NT-
roBNP levels are now firmly established as validated
iagnostic markers for acute HF (1,17). Across the spec-
rum of HF stages, these peptides are independent predic-
ors of HF events or mortality (17). Recent studies have
hown that serial measurements of BNP or NT-proBNP
rovide incremental risk prediction in acute decompensated
r chronic HF settings, with the most recent peptide measure-
ent providing the greatest prognostic value (18,19).
A number of studies in the community setting have tested
hether biomarker measurement at a single time point can
mprove the prediction of cardiovascular events (13,14).
hese studies show a modest improvement in detection of
ardiovascular mortality by risk models that include biomar-
ers compared with models containing conventional risk
actors and demographic data alone (13,14). Much of this
mprovement in risk stratification reflects more accurate
lassification of subjects with low biomarker levels who are
ess likely to suffer events despite the presence of conven-
ional risk factors for cardiovascular disease (13).
In a study described in this issue of the Journal, deFilippi
t al. (20) have taken the concept of biomarker testing for
arly detection a step further by evaluating whether serial
easurement of NT-proBNP improved the prediction of
ncident HF and of cardiovascular mortality in elderly
ubjects participating in the CHS (Cardiovascular Health
tudy). Detailed data had already been collected at baseline
nd follow-up, and patients with established HF were
xcluded. The investigators measured NT-proBNP levels
sing stored plasma from 4,312 participants at baseline.
uring a median follow-up of 11.9 years, there were 2.6
ew HF events per 100 person-years and 2.1 cardiovascular
eaths per 100 person-years. Baseline NT-proBNP levels
ere independent predictors of clinical events, with an
nflection point in risk at the 70th percentile corresponding
o an NT-proBNP concentration of 190 pg/ml. After
djustment for conventional risk factors and echocardio-
raphic data, the investigators noted a 2.5-fold higher risk
f HF or cardiovascular death for subjects within the
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owest quintile.
Within the select group of 2,975 participants with a
urther plasma sample taken at 3 years, the investigators
howed that a second NT-proBNP level provided incre-
ental prognostic value. The risk for future HF events or
ortality could be further stratified by whether NT-
roBNP levels increased or decreased at follow-up. The
ighest risk was seen in subjects with higher baseline
T-proBNP levels (190 pg/ml) who had a 25% in-
rease in peptide levels at follow-up, whereas subjects in
hom peptide levels decreased by 25% had significantly
ower risk. Even in subjects with a baseline level below 190
g/ml, an increase in NT-proBNP levels at follow-up by
25% to a level higher than 190 pg/ml was associated with
ignificantly higher risk of adverse clinical events.
Appropriately, the investigators tested the incremental
alue of baseline and follow-up NT-proBNP levels com-
ared with prediction of HF or mortality based on conven-
ional and demographic factors alone (21). First, they
howed that addition of baseline and then follow-up NT-
roBNP levels resulted in statistically significant improve-
ents in the C-statistic derived from receiver-operator
haracteristic curve analysis. Second, and more helpfully,
hey showed that incorporation of baseline and follow-up
T-proBNP levels resulted in more accurate classification
f 10-year risk for HF or mortality, with between 4.5%
nd 7.9% of subjects being more accurately classified
hen baseline and/or follow-up NT-proBNP levels were
ncorporated.
The current study is commendable in highlighting the
oncept of dynamic risk stratification based on serial assess-
ent. The findings confirm a modest improvement in risk
tratification by including a single measurement of NT-
roBNP levels (13,14,16). The investigators take this a step
urther by showing that serial NT-proBNP measurement at
later time provides a further modest improvement in risk
tratification. The relatively modest impact of NT-proBNP
n risk prediction is likely to reflect several factors, including
he impact of age and comorbidity, such as renal dysfunc-
ion, on NT-proBNP levels and the relatively low accuracy
or detection of left ventricular systolic or diastolic dysfunc-
ion by these peptides (17). Whether the improvement in
isk stratification achieved by performing serial NT-
roBNP testing crosses a threshold of definite clinical value
eeds further evaluation, with particular consideration of
he cost effectiveness of such a strategy (21). The latter will
e influenced by event rates and to a larger extent by
hether early detection using NT-proBNP levels can alter
anagement to improve outcomes beyond those achieved
y optimal treatment of conventional risk factors. The
oncept of using serial NT-proBNP levels to guide the
anagement of established chronic HF therapy is the focus
f several recent and ongoing studies (22,23). It is salient to
ote that this strategy had the least success in older subjects,n whom NT-proBNP levels and treatment choices may benfluenced by comorbidity and other factors (22,23). The
urrent study raises other questions, including the optimal
ime interval for serial biomarker testing and the relative
hange that best identifies a risk of future events. An
nterval of 3 years, as in this study, is reasonable when event
ates are low, but may miss a proportion of events in
igh-risk subjects. The variability seen in NT-proBNP
evels measured at an interval in stable individuals has been
ighlighted in a number of studies. This variability is in
mall part attributable to assay characteristics, but largely
eflects biological variability as a result of factors influencing
ecretion and clearance of NT-proBNP (24). In elderly
atients, these factors could include myocardial ischemia,
hanges in renal function, or neurohormonal factors, all of
hich may modify clinical outcome (24). The findings from
his study and others suggest that changes in NT-proBNP
arallel the risk of adverse clinical outcomes (18,19).
In the acute HF setting, a second peptide measurement
fter treatment or at discharge is almost always helpful (18).
hould we now advocate serial NT-proBNP testing of
lderly subjects in the community to improve screening and
isk stratification for HF? The current study suggests that
here may be a benefit from such a strategy, but leaves some
uestions unanswered. Its findings should encourage further
esearch into the role of serial risk assessment for heart
ailure using biomarkers.
eprint requests and correspondence: Dr. Richard W. Trough-
on, Department of Medicine, University of Otago, Christchurch,
.O. Box 4345, Christchurch 8140, New Zealand. E-mail:
ichard.troughton@cdhb.govt.nz.
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